Please login to the form below
Steglatro
This page shows the latest Steglatro news and features for those working in and with pharma, biotech and healthcare.
NICE recommends MSD’s diabetes drug Steglatro
NICE has cleared MSD’s type 2 diabetes treatment Steglatro for routine NHS use in combination with metformin, or as a monotherapy for those who are intolerant to the anti-diabetic ... MSD is hoping Steglatro can take market share from other more
Latest news
-
The year of the blockbuster
Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabetes, but SGLT-2 inhibitor Steglatro will be a late ... Steglatro has now been launched in the US and an EMA
-
FDA’s year-end approvals take annual tally to 46
Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... Steglatro and Steglujan are
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
NICE – but not enough
Steglatro launched as a new SGLT2 in early 2019 and was quickly bolstered by two NICE TAs. ... Armed with positive NICE guidance, MSD did a great job of getting Steglatro on formulary.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
